Manabu Natsumeda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8664429/publications.pdf

Version: 2024-02-01

74	2,498	430442	214527
papers	citations	18 h-index	47 g-index

80	80	80	4041
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. International Journal of Clinical Oncology, 2022, 27, 77-94.	1.0	5
2	Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide. Cancers, 2022, 14, 770.	1.7	2
3	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. Clinical Journal of Gastroenterology, 2022, 15, 413-418.	0.4	7
4	Visualization of cortical activation in human brain by flavoprotein fluorescence imaging. Journal of Neurosurgery, 2022, , 1-9.	0.9	0
5	Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group. Brain Tumor Pathology, 2022, 39, 139-150.	1.1	4
6	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma. Clinical Cancer Research, 2022, 28, 2425-2439.	3.2	17
7	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. Molecular Cancer Therapeutics, 2022, 21, 715-726.	1.9	11
8	GLI3ÂIs Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2021, 80, 129-136.	0.9	5
9	So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?. Neuro-Oncology, 2021, 23, 295-303.	0.6	24
10	Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imagingâ€"A controversy. Neuro-Oncology Advances, 2021, 3, vdab086.	0.4	7
11	Topoisomerase IIÎ² immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Childrenâ€™s Cancer Group. Brain Tumor Pathology, 2021, 38, 109-121.	1.1	1
12	Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas. Diagnostics, 2021, 11, 681.	1.3	8
13	Four-dimensional multifusion imaging for assessment of meningioma hemodynamics. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2021, 24, 101118.	0.2	1
14	Lessâ€invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysisâ€"A case report. Clinical Case Reports (discontinued), 2021, 9, e04551.	0.2	2
15	Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. Brain Tumor Pathology, 2021, 38, 228-233.	1.1	9
16	Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. International Journal of Clinical Oncology, 2021, 26, 2205-2215.	1.0	6
17	Endovascular treatment of an infectious aneurysm using the selective provocative test and transcranial motor evoked potential monitoring under general anesthesia: a case report. Acta Neurochirurgica, 2021, , 1.	0.9	0
18	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td (edition)	4.3	1,430

#	Article	IF	Citations
19	Choroid Plexus Papilloma in the Fourth Ventricle Associated with Pheochromocytoma: A Case Report. NMC Case Report Journal, 2021, 8, 727-731.	0.2	0
20	Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of â€œFalse-Positiveâ€•Cases. Diagnostics, 2021, 11, 2129.	1.3	4
21	GEN-7 Liquid biopsy in brain tumor patients -The present and future-. Neuro-Oncology Advances, 2021, 3, vi4-vi4.	0.4	0
22	STMO-16 The usability of Detailed pre-operative 3D simulation image for Tumor Resection of High grade glioma. Neuro-Oncology Advances, 2021, 3, vi13-vi14.	0.4	0
23	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. Cancer Research, 2020, 80, 5330-5343.	0.4	19
24	Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group. Neurologia Medico-Chirurgica, 2020, 60, 543-552.	1.0	4
25	MBRS-06. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii399-iii400.	0.6	0
26	MBRS-32. TOPOISOMERASE II Î² INDUCES NEURONAL, BUT NOT GLIAL, DIFFERENTIATION IN MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii404-iii404.	0.6	0
27	ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group. Neuro-Oncology Advances, 2020, 2, ii17-ii17.	0.4	0
28	ACT-05 Present and future of precision-based medicine using cancer genome panels. Neuro-Oncology Advances, 2020, 2, ii8-ii8.	0.4	0
29	Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leukemia and Lymphoma, 2019, 60, 3587-3589.	0.6	18
30	Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. Acta Neuropathologica Communications, 2019, 7, 119.	2.4	47
31	Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period. World Neurosurgery, 2019, 128, e982-e988.	0.7	20
32	Malignant Hyperthermia and Cerebral Venous Sinus Thrombosis After Ventriculoperitoneal Shunt in Infant with Schizencephaly and COL4A1 Mutation. World Neurosurgery, 2019, 127, 446-450.	0.7	8
33	EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma. Neurologia Medico-Chirurgica, 2019, 59, 89-97.	1.0	10
34	ML-11 DETECTION OF MYD88 MUTATIONS FROM CELL FREE DNA AIDS IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM LYMPHOMAS. Neuro-Oncology Advances, 2019, 1, ii34-ii34.	0.4	0
35	COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA. Neuro-Oncology Advances, 2019, 1, ii44-ii44.	0.4	0
36	High Detection Rate of MYD88 Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas. JCO Precision Oncology, 2019, 3, 1-13.	1.5	21

#	Article	IF	Citations
37	Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for highâ€MYC medulloblastoma. Neuropathology, 2019, 39, 71-77.	0.7	8
38	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. Frontiers in Oncology, 2019, 9, 1568.	1.3	18
39	High Incidence of Deep Vein Thrombosis in the Perioperative Period of Neurosurgical Patients. World Neurosurgery, 2018, 112, e103-e112.	0.7	29
40	Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. Neurosurgical Review, 2018, 41, 641-647.	1.2	18
41	PATH-46. NEURONAL DIFFERENTIATION IS INDUCED BY Gli3 IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, vi168-vi169.	0.6	0
42	PATH-50. HIGH DETECTION RATE OF MYD88MUTATIONS IN CEREBROSPINAL FLUID FROM PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMAS. Neuro-Oncology, 2018, 20, vi169-vi169.	0.6	0
43	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. Neurologia Medico-Chirurgica, 2018, 58, 290-295.	1.0	29
44	Late relapse of primary central nervous system lymphoma. Leukemia and Lymphoma, 2017, 58, 475-477.	0.6	8
45	The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Letters, 2017, 400, 110-116.	3.2	52
46	Long-term survivors of primary central nervous system lymphoma. Japanese Journal of Clinical Oncology, 2017, 47, 101-107.	0.6	5
47	Targeting cancer stemâ€like cells in glioblastoma and colorectal cancer through metabolic pathways. International Journal of Cancer, 2017, 140, 10-22.	2.3	51
48	PATH-54. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA. Neuro-Oncology, 2017, 19, vi183-vi183.	0.6	0
49	HG-69CELL CULTURE CONDITIONS AFFECT DIFFUSE INTRINSIC PONTINE GLIOMA EPIGENETICS AND RESPONSE TO THERAPEUTIC AGENTS. Neuro-Oncology, 2016, 18, iii64.1-iii64.	0.6	0
50	Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells. Stem Cells, 2016, 34, 2016-2025.	1.4	9
51	Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres. Brain Pathology, 2016, 26, 713-723.	2.1	42
52	Immunohistochemical profiles of I<scp>DH</scp>1, <scp>MGMT</scp> and <scp>P</scp>53: Practical significance for prognostication of patients with diffuse gliomas. Neuropathology, 2015, 35, 324-335.	0.7	52
53	PTPS-22DUAL mTOR KINASE INHIBITOR (MLN0128) MARKEDLY INDUCES GROWTH SUPPRESSION AND APOPTOSIS IN DIFFUSE INTRINSIC PONTINE GLIOMA CELL LINES. Neuro-Oncology, 2015, 17, v184.1-v184.	0.6	0
54	MTR-10PHARMACOLOGICAL NOTCH BLOCKADE IN GLIOMAS INDUCES AUTOPHAGY AND COMBINATION TREATMENT WITH AN AUTOPHAGY INHIBITOR INCREASES TUMOR CELL DEATH. Neuro-Oncology, 2015, 17, v126.2-v126.	0.6	0

#	Article	IF	Citations
55	Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. Journal of Neuropathology and Experimental Neurology, 2015, 74, 889-900.	0.9	54
56	Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Acta Neuropathologica Communications, 2014, 2, 158.	2.4	48
57	DS-02 * INDUCTION OF AUTOPHAGY MARKERS IN GLIOMAS FOLLOWING PHARMACOLOGICAL NOTCH BLOCKADE. Neuro-Oncology, 2014, 16, v65-v65.	0.6	0
58	Central nervous system lymphoma with the â€œtarget signâ€•on magnetic resonance imaging mimicking cerebral toxoplasmosis. Neurology and Clinical Neuroscience, 2014, 2, 21-22.	0.2	0
59	Neuronal differentiation associated with <scp>Gli3</scp> expression predicts favorable outcome for patients with medulloblastoma. Neuropathology, 2014, 34, 1-10.	0.7	12
60	Suppressed Expression of Autophagosomal Protein <scp>LC3</scp> in Cortical Tubers of Tuberous Sclerosis Complex. Brain Pathology, 2013, 23, 254-262.	2.1	14
61	Factors affecting functional outcomes in long-term survivors of intracranial germinomas: a 20-year experience in a single institution. Journal of Neurosurgery: Pediatrics, 2013, 11, 454-463.	0.8	38
62	Gene expression signatureâ€based prognostic risk score in patients with glioblastoma. Cancer Science, 2013, 104, 1205-1210.	1.7	56
63	Epsteinâ€<scp>B</scp>arr virusâ€associated primary central nervous system cytotoxic <scp>T</scp>â€cell lymphoma. Neuropathology, 2013, 33, 436-441.	0.7	22
64	Advantages of Dose-dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution. Neurologia Medico-Chirurgica, 2013, 53, 797-804.	1.0	11
65	Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. International Journal of Oncology, 2012, 40, 721-30.	1.4	6
66	Effectiveness of Maximal Safe Resection for Glioblastoma Including Elderly and Low Karnofsky Performance Status Patients: Retrospective Review at a Single Institute. Neurologia Medico-Chirurgica, 2012, 52, 570-576.	1.0	18
67	Near-infrared spectroscopic study and the Wada test for presurgical evaluation of expressive and receptive language functions in glioma patients: With a case report of dissociated language functions. Neuroscience Letters, 2012, 510, 104-109.	1.0	14
68	Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report. Pituitary, 2012, 15, 110-115.	1.6	24
69	Anaplastic astrocytoma with angiocentric ependymal differentiation. Neuropathology, 2011, 31, 292-298.	0.7	10
70	Induction of autophagy in temozolomide treated malignant gliomas. Neuropathology, 2011, 31, 486-493.	0.7	53
71	Synchronized multiple regression of diagnostic radiation-induced rather than spontaneous: disseminated primary intracranial germinoma in a woman: a case report. Journal of Medical Case Reports, 2011, 5, 39.	0.4	11
72	Indication of intraoperative immunohistochemistry for accurate pathological diagnosis of brain tumors. Brain Tumor Pathology, 2011, 28, 239-246.	1.1	9

#	Article	IF	Citations
73	Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection. Journal of Neurosurgery, 2011, 114, 1224-1231.	0.9	56
74	Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. Neuropathology, 2010, 30, 443-448.	0.7	29